• Citer

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

par Willemze, Roel;Suciu, Stefan ;Meloni, Giovanna;Labar, Boris;Marie, Jean Pierre;Halkes, Constantijn CJ;Muus, Petra;Mistrik, Martin;Amadori, Sergio;Specchia, Giorgina;Fabbiano, Francesco;Nobile, Francesco;Sborgia, Marco;Camera, Andrea;Selleslag, Dominik;Lefrère, Francois;Magro, Domenico;Sica, Simona;Cantore, Nicola;Beksac, Meral Sinan;Berneman, Zwi Nisan;Thomas, Xavier;Melillo, Lorella;Guimaraes, Jose E;Leoni, Pietro;Luppi, Mario;Mitra, Maria E;Bron, Dominique ;Fillet, Georges;Marijt, Erik EW;Venditti, Adriano;Hagemeijer, Anne;Mancini, M.;Jansen, Joop;Cilloni, Daniela;Meert, L;Fazi, Paola;Vignetti, Marco;Trisolini, Silvia SM;Mandelli, Franco;De Witte, Theo
Référence Journal of clinical oncology, 32, 3, page (219-228)
Publication Publié, 2014-01

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.